Stock Market News·2025-10-02 06:00Group 1: Pharmaceutical Industry - The Trump administration announced a deal with Pfizer to reduce drug prices for Americans through the "TrumpRx" website, offering discounts of up to 85% on certain products and a commitment to "Most-Favored-Nation" pricing for new drugs in Medicaid programs [2] - Pfizer's stock surged by 6.8% on September 30 and achieved a total gain of 14.2% over two trading days, pushing its share price above $27 by October 1 [3] - Other pharmaceutical companies also experienced significant stock increases, with AstraZeneca rising by 6.87%, Sanofi by 8.5%, and Eli Lilly by 8% on October 1 [3] Group 2: Market Reactions - Analysts expressed optimism regarding the deal, suggesting it could pave the way for other pharmaceutical companies to follow suit, while also providing a political win for the administration without imposing severe pricing demands [4] - Despite the U.S. government entering a shutdown, major U.S. indices continued to rise, with the Dow Jones Industrial Average closing at a record high of 46,441.10 and the S&P 500 at 6,711.20 on October 1 [10][11] - The market's resilience was attributed to investors focusing on weak labor market data, which raised expectations for further Federal Reserve easing, rather than the political turmoil [11] Group 3: Tariff Impacts - New tariffs were announced on lumber and furniture, with a 10% tariff on softwood timber and a 25% duty on kitchen cabinets and upholstered wood furniture, set to escalate to 30% and 50% respectively by January 1, 2026 [5] - The Canadian lumber sector faces a combined tariff rate of 45.16%, creating significant challenges for the industry [5] - The entertainment industry reacted negatively to the threat of a 100% tariff on foreign films, with stock prices for major companies like Netflix declining [7][8]